Pharmafile Logo

In-person, hybrid, or digital? State of Pharma meetings and events in 2024

March 18, 2024 |  

We’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put the idea of in-person meetings being superior to rest.

- PMLiVE

Whether we’re talking offices, medical congresses, or advisory board meetings, the term “hybrid” is often used to signal the ideal state. The place where everyone’s needs are being met. The best of both worlds. In the era of digital transformation, it is predicted that 2024 will be the year that finally cements hybrid meetings as the norm (1), with all-virtual meetings continuing to be a popular option. Yet, some people are holding onto the idea of in-person meetings being superior. In this article, we’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put this idea to rest.

Why in-person-only should be a thing of the past

I’ve written and talked about the blindspots of in-person meetings for over 16 years now, but it’s only been in the past few years that the benefits of virtual engagements have gained mainstream acceptance. There are multiple reasons why in-person-only meetings should be laid to rest, including, but not limited to, the facts that they are:

  • Expensive
  • Associated with a large environmental footprint
  • Inflexible and not accommodating to everyone’s schedules, work or personal commitments, and preferences
  • Susceptible to last-minute no-shows due to flight delays or poor driving conditions

Specifically for advisory boards and other insight-gathering initiatives, the in-person-only approach comes with additional pain points such as:

  • Valuable time wasted on didactic data presentations
  • Very limited “air time” per participant
  • Uneven share of voice, with more extroverted or senior advisors tending to take up more speaking time
  • A tendency for answers to be “knee-jerk reactions” rather than thought-through responses and for people to simply ‘agree’ with others
  • Limited ability to dive deeper into interesting or controversial ideas
  • Suboptimal diversity of advisors due to potential geographic or language barriers

Most important, though, is the fact that participants don’t want only in-person meetings. Based on our survey of hundreds of healthcare provider advisors in 2022–2023, over three-quarters stated that they prefer virtual/hybrid meetings, with the convenience and flexibility of digital meetings rated as the top benefits…

[Read the full article here]

This content was provided by Impetus Digital

Company Details

 Latest Content from  Impetus Digital 

Importance of Patient Advocacy in Improving Healthcare

Eva Villalba, Executive Director of the Quebec Cancer Coalition, explores the importance of patient advocacy in improving healthcare. Among many other things, we dive into how the industry can help support...

Improving Patient Care by Removing Barriers to Drug Accessibility

Alan Birch, Founder & President of Drug Access Canada, discusses all things drug access and reimbursement. Among many other things, we explore the hurdles faced by patients and drug access navigators and...

Reimagining the Patient Journey

Kimberly Tableman, CEO at Medicine X, discusses a myriad of topics related to digital transformation and patient centricity, including how digital health technologies can be used to reimagine the patient...

Environmental impact of in-person vs. virtual meetings

Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...

Leadership Lessons Learned from the Pandemic

Alok Kanti, President & CEO of Bayer Canada, discusses a variety of topics, including his experience with leading an entire organization through the COVID-19 pandemic and where he sees digital health...

Overcoming Behavioral Health Access Limitations Through Telemedicine

Phil Hirsh, PhD, Founder & Chief Executive at Synergia Integrated teleBehavioral Health; and Craig Wright, MD, Senior Physician Executive and Consultant, discuss a range of topics surrounding telemedicine and other digital health...

Commercial Execution Strategies During & After the Pandemic

Frank Armenante, Director of Commercial Execution at Novo Nordisk, discusses a range of topics, from the impact of COVID-19 on commercial operations and the digitization of Pharma to his leadership lessons...

Top 10 Reasons Why Virtual Collaboration and Medical Education Will Persist in the New Normal

Even after the pandemic is long behind us, virtual collaboration will become mainstay in Pharma.

Pharma, Technology, and Healthcare in the New Normal

Brian Canestraro, General Manager at Intercept Pharmaceuticals, discusses a range of hot topics, from Brian’s leadership lessons and tips to the impact of the COVID-19 pandemic on the way that Pharma...

Solving the Caregiver Crisis Through Technology

Curtis Khan, CEO and Founder of BookJane, discusses the ongoing caregiver crisis and how BookJane’s solutions and other digital technologies can help to close this gap. We also delve into how...